The global glioblastoma multiforme treatment market size was estimated to be US$ 2.3 billion in 2021 and is expected grow at a CAGR of 7.5% between 2023 to 2032.
Glioblastoma multiforme (GBM) is a grade IV WHO malignant tumor with astrocytic differentiation. GBM is the most common clinically diagnosed central nervous system (CNS) oncological condition. These kinds of tumors are of wide variety and description in historical medical reports. Multifomity of GBM is established by the introduction of molecular and genetic tests. Different genotypes bear similar histomorphology and IHC image and even some aspects of gliomagenesis.
For primary glioblastoma multiforme to occur a specific trigger mutation needs to occur in a GBM stem cell and for a secondary GBM to occur a slow aggregation of individual mutations without a distinct trigger mutation needs to occur. Since such malignancies were first described more than 200 years ago, the knowledge of GBM is closely related to medical knowledge of the CNS.
There is an increase in demand for glioblastoma multiforme treatment due to which manufacturers are increasing the supply for new products and pipelines of products. Furthermore, there is also increased event participation in the market which ultimately enhances growth of the market.
Glioblastoma Multiforme Treatment Market dynamics
Growing prevalence of glioblastoma multiforme
Approximately 80% of all central nervous system (CNS) primary malignant tumors are Glioblastoma multiforme (GBM). It is classified as a grade 4 astrocytic and oligodendroglial tumor by the World Health Organization. There is a demand for early detection and diagnosis. Advent of new technology has propelled the global glioblastoma multiforme treatment market.
Increasing research and development (R&D)
Various new biological drugs are introduced each year due to increasing R&D activities in molecular biotechnology and gene therapy for malignant diseases. These news drugs assist is reducing side effects of treatments and create more acceptance amongst patients. The approval of new treatment options will increase the life expectancy of patients living with glioblastoma multiforme. Furthermore, increasing collaborations between drug researchers and patients will bolster this market’s growth
Increasing drug approvals
Due to the high fatality rate of this disease, the glioblastoma multiforme treatment industry has witnessed numerous drug approvals in recent years. Moreover, the increase of activities by the regulatory authorities to approve new treatments has further bolstered this market growth.
Glioblastoma Multiforme Treatment Market challenges
High cost of glioblastoma multiforme treatment
The diagnostic tools and techniques used for the diagnosis of glioblastoma multiforme include:
- Radiation therapy
Glioblastoma multiforme is usually diagnosed at advanced stages and this often results in a poor prognosis. Developing drugs for GBM is a highly complex and costly process that requires significant investments, clinical trial expertise, quality systems, scientific standards and technical capabilities. Drug manufacturers are required to invest in clinical trials and post-approval safety monitoring programs due to stringent regulations required by the regulators. Treating GBM using new and advanced drugs and the high cost associated with it will act as a major restraining factor for growth of this market
Glioblastoma Multiforme Treatment Market Share Analysis, by Geography (2021)
The major players covered in the Glioblastoma Multiforme Treatment Market report are Hoffmann-La Roche AG, Amgen Inc, Merck & Co Inc, Pfizer Inc, Varian Medical Systems Inc, ZEISS International, Amneal Pharmaceuticals LLC, Elekta, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, Eckert & Ziegle, Accord Healthcare, Angiochem, ANI Pharmaceuticals Inc, Arbor Pharmaceuticals LLC, AstraZeneca, Cantex Pharmaceuticals Inc, CELON LABS, Diffusion Pharmaceuticals Inc, EnGeneIC, ERC.SA., Genenta science, Jazz Pharmaceuticals Inc, Loxo Oncology, Novartis AG, VBL THERAPEUTICS, Viatris Inc, Zydus Pharmaceuticals Incand others.
Market Segmentation as below:
- Primary (De Novo)
By Patient Type
By Drug Type
By Route of Administration
By End User
By Distribution Channel
- North America
- United States
- Rest of North America
- United Kingdom
- Rest of Europe
- Asia Pacific
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of the Middle East & Africa
- South America
- Rest of South America